The Centre has granted in-principle approval to the NPPA to allow a price increase for two essential chemotherapy drugs: Cisplatin and Carboplatin. This move, executed under Para 19 of the Drugs (Prices Control) Order (DPCO), aims to resolve a nationwide supply crunch that has disrupted cancer treatment protocols at major hospitals. The shortage was primarily driven by the soaring global cost of platinum, a key raw material, which made local production economically unviable for manufacturers under existing price caps.

Key points:

• Emergency Powers: Under Para 19 of the DPCO, the government and the NPPA possess extraordinary authority to revise the ceiling or retail price of any drug in the “public interest” during exceptional circumstances.

• The “Platinum” Crisis: The Active Pharmaceutical Ingredient (API) for these drugs relies on platinum. Global prices for this metal have surged dramatically (by nearly 250% in recent times), compounded by supply chain disruptions, geopolitical conflicts (such as in West Asia), and import duty hikes.

• Impact on Patients: These drugs serve as the “backbone” of treatment for many solid tumors, including ovarian, cervical, lung, and head-and-neck cancers. Prolonged shortages were forcing hospitals to ration supplies, leading to dangerous therapy delays.

• Balance of Interests: While higher prices may temporarily impact patient costs, the government’s priority is to restore uninterrupted supply, as there are currently no effective clinical substitutes for these platinum-based agents.

• Regulatory Approach: This is a targeted intervention. The government has clarified that it is not considering a blanket price increase for all essential medicines but is instead examining specific, justified cases where input costs have risen sharply.

the National Pharmaceutical Pricing Authority (NPPA):

• Establishment: Constituted on August 29, 1997, as an attached office of the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers.

• Mandate: It acts as an independent regulator for pricing drugs and ensuring their availability and accessibility.

• Core Functions:

  • Fixing and Revising Prices: It determines ceiling prices for essential medicines notified under Schedule-I of the DPCO.

  • Monitoring: It tracks the availability of drugs and ensures companies comply with notified price ceilings.

  • Policy Advice: It renders advice to the government on pharmaceutical policies.

  • Public Grievance: It operates platforms like ‘Pharma Sahi Dam’ and ‘Pharma Jan Samadhan’ to inform the public about drug prices and address grievances.

राष्ट्रीय औषधि मूल्य निर्धारण प्राधिकरण (NPPA):

चर्चा में क्यों है? (Why in news?):

केंद्र सरकार ने NPPA को दो आवश्यक कीमोथेरेपी दवाओं: सिसप्लेटिन (Cisplatin) और कार्बोप्लेटिन (Carboplatin) की कीमतों में वृद्धि करने के लिए सैद्धांतिक मंजूरी दे दी है। यह कदम ड्रग्स (प्राइस कंट्रोल) ऑर्डर (DPCO) के पैरा 19 के तहत उठाया गया है, जिसका उद्देश्य देश भर के अस्पतालों में चल रहे दवाओं के संकट को समाप्त करना है। यह कमी मुख्य रूप से प्लेटिनम की बढ़ती वैश्विक कीमतों के कारण हुई है, जिससे मौजूदा मूल्य सीमाओं (price caps) के तहत निर्माताओं के लिए इनका उत्पादन करना आर्थिक रूप से कठिन हो गया था।

मुख्य बिंदु (Key points):

• आपातकालीन शक्तियां: DPCO के पैरा 19 के तहत, सरकार और NPPA को असाधारण परिस्थितियों में “जनहित” में किसी भी दवा की अधिकतम मूल्य (ceiling price) या खुदरा मूल्य तय करने या संशोधित करने की विशेष शक्तियां प्राप्त हैं।

• “प्लेटिनम” संकट: इन दवाओं के लिए मुख्य कच्चा माल प्लेटिनम है। हाल ही में इसके वैश्विक दाम लगभग 250% तक बढ़ गए हैं, साथ ही आपूर्ति श्रृंखला में बाधा और आयात शुल्क में बढ़ोतरी ने स्थिति को और गंभीर बना दिया है।

• रोगियों पर प्रभाव: ये दवाएं ओवेरियन, सर्वाइकल, फेफड़ों और सिर-गर्दन के कैंसर के इलाज के लिए “आधारभूत” (backbone) हैं। लंबे समय तक इनकी कमी के कारण अस्पतालों को आपूर्ति सीमित करनी पड़ रही थी, जिससे कैंसर का इलाज बाधित हो रहा था।

• संतुलन की आवश्यकता: हालांकि बढ़ी हुई कीमतें अस्थायी रूप से मरीजों पर बोझ डाल सकती हैं, लेकिन सरकार की प्राथमिकता दवाओं की निर्बाध आपूर्ति सुनिश्चित करना है, क्योंकि इन दवाओं का अभी कोई प्रभावी क्लिनिकल विकल्प उपलब्ध नहीं है।

• नियामक दृष्टिकोण: यह एक लक्षित हस्तक्षेप है। सरकार ने स्पष्ट किया है कि वह सभी आवश्यक दवाओं की कीमतों में कोई “बल्क” बढ़ोतरी नहीं कर रही है, बल्कि केवल उन विशिष्ट मामलों की जांच कर रही है जहां इनपुट लागत में भारी वृद्धि हुई है।

राष्ट्रीय औषधि मूल्य निर्धारण प्राधिकरण (NPPA) के बारे में:

• स्थापना: 29 अगस्त 1997 को रसायन और उर्वरक मंत्रालय के फार्मास्यूटिकल्स विभाग (DoP) के एक संबद्ध कार्यालय के रूप में।

• जनादेश: यह दवाओं की कीमतों के विनियमन और उनकी उपलब्धता सुनिश्चित करने के लिए एक स्वतंत्र नियामक के रूप में कार्य करता है।

• प्रमुख कार्य:

  • मूल्य निर्धारण: आवश्यक दवाओं के लिए अधिकतम मूल्य (ceiling price) निर्धारित करना।

  • निगरानी: दवाओं की उपलब्धता पर नज़र रखना और कंपनियों द्वारा मूल्य सीमाओं के अनुपालन को सुनिश्चित करना।

  • नीतिगत सलाह: फार्मास्युटिकल नीतियों पर सरकार को सलाह देना।

  • जन शिकायत: ‘फार्मा सही दाम’ और ‘फार्मा जन समाधान’ जैसे प्लेटफॉर्म के माध्यम से जनता को जागरूक करना।

Key Performance Indicators (Successes):

The survey indicates a positive trajectory in critical health parameters, reflecting the impact of targeted national missions (e.g., Poshan Abhiyaan, Mission Indradhanush).

• Maternal Health: Sustained improvement in institutional deliveries and antenatal care (ANC) registration.

• Child Nutrition: * Stunting: Declined significantly from 35.5% (NFHS-5) to 29.3%.

  • Severe Wasting: Decreased from 7.7% to 5.2%.

• Immunization Coverage: Marked increase in full immunization coverage among children, bolstered by aggressive outreach and digital tracking (U-WIN platform).

Emerging Challenges (The “Double Burden”):

While India has made progress in addressing undernutrition, it is now confronting a “double burden of malnutrition” characterized by the rise of non-communicable diseases (NCDs).

• Rising Obesity: A significant shift toward unhealthy BMI levels in both urban and rural populations.

• Lifestyle Diseases: Increasing incidence of hypertension, diabetes, and cardiovascular conditions linked to sedentary lifestyles and dietary transitions (high-processed food intake).

Implications for Public Health Policy

1. Shift in Focus: Public health strategy must evolve from focusing solely on “food security and caloric intake” to “nutritional quality and metabolic health.”

2. Integrated NCD Management: Strengthening primary healthcare centers (AB-HWCs) to provide early screening and management for lifestyle diseases.

3. Behavioral Change Communication (BCC): The need for targeted campaigns to promote physical activity and balanced diets, moving beyond the “Malnutrition-free India” mandate.

4. District-Level Intervention: The wide coverage of NFHS-6 allows for hyper-local health planning, focusing resources on the 715 districts based on their specific health profiles.

Way Forward:

• Data-Driven Governance: Utilize the granular district-level data of NFHS-6 to design bottom-up health policies.

• Whole-of-Government Approach: Convergence between the Ministry of Women and Child Development (nutrition) and the Ministry of Health (NCD management).

• Focus on Preventive Healthcare: Investing in community awareness programs to mitigate the long-term economic burden of lifestyle diseases.

Conclusion

The NFHS-6 data reveals an India in transition. While the decline in stunting and wasting proves the efficacy of India’s foundational health interventions, the rise in obesity signals an urgent need to reorient the health system toward addressing the metabolic and lifestyle-related risks of the 21st century.

 1. Total Fertility Rate (TFR):

The Total Fertility Rate represents the average number of children born to a woman during her reproductive years.

• Below Replacement Level: India’s TFR has remained stable at 1.9 for the fifth consecutive year, well below the replacement level of 2.1.

  • Note: A TFR of 2.1 is the population replacement level at which a population exactly replaces itself from one generation to the next without migration. India is now firmly on a trajectory toward population stabilization.

• Rural vs. Urban Divide:

  • Rural India: The TFR is steady at 2.1 (exactly at the replacement level).

  • Urban India: The TFR has dropped to a low of 1.5. Urban fertility has consistently lagged below the replacement threshold since 2005.

 2. Birth Rate & Sex Ratio:

• Crude Birth Rate (CBR): The number of live births per 1,000 population witnessed a marginal decline from 18.4 in the previous assessment cycle to 18.3.

  • Rural: Declined from 20.3 to 20.2.

  • Urban: Declined from 14.9 to 14.7.

• Sex Ratio at Birth: The number of female births per 1,000 male births (based on a three-year moving average) showed a slight improvement, ticking up from 917 (2021-23) to 918.

 3. Mortality Rates & Critical Shifts:

• Crude Death Rate (CDR): The number of deaths per 1,000 population remains stagnant at 6.4 (6.8 in rural sectors and dropping slightly from 5.6 to 5.5 in urban centers).

• The Post-COVID Anomaly (Area of Concern): The overall death rate (6.4) remains notably higher than pre-pandemic baselines observed in 2019 and 2020, where it stood at 6.0. While significantly down from the pandemic peak of 7.5 in 2021, the failure to return to pre-COVID levels points to lingering public health vulnerabilities.

• Infant Mortality Rate (IMR): The number of infant deaths under one year of age per 1,000 live births continues its slow, steady decline, dropping from 25 to 24.

4. Major Causes of Death (Epidemiological Transition):

The report highlights a significant shift in the disease burden and causes of mortality across India:

A. Respiratory Infections

• Deaths attributed to respiratory infections stood at 5.7% (three-year average). While this marks a steep decline from the peak pandemic years (where it touched 10% in 2020-22), it remains significantly elevated compared to the pre-pandemic rate of 3.6% (2017-19).

B. Non-Communicable Diseases (NCDs) & Cardiovascular Issues

• Cardiovascular Diseases (CVDs): Heart disease remains the leading cause of death in India, with its share growing from 31% to 32.1%. Health experts attribute this to long-term post-COVID morbidity, which has aggravated cardiac issues across demographic segments.

• NCD Dominance: As acute pandemic infections faded, the cumulative share of deaths caused by Non-Communicable Diseases—including cancers, diabetes, and cardiovascular failures—rose from 56.7% to 60.1%.

C. External Causes: Accidents and Mental Health

• Motor Vehicle Accidents: The share of deaths resulting from road accidents increased from 2.9% to 3.2%.

• Suicides: Deaths by suicide grew as a proportion of total mortalities, rising from 2.5% to 2.8%.

  • Corroborative Data: This upward trend matches recent findings from the National Crime Records Bureau’s (NCRB) Accidental Deaths & Suicides in India (ADSI) report, highlighting growing socio-economic stress and road safety challenges.

Key Policy Takeaways for Mains Analysis:

1. Irreversible Demographic Transition: Maintaining a TFR below 2.1 for half a decade confirms that India has peaked in terms of explosive population growth. Policy focus must transition from “population control” to managing an aging workforce and optimizing the tail-end of the demographic dividend.

2. The “Long COVID” Footprint: The persistent elevation of death rates above pre-pandemic baselines, coupled with rising cardiac and respiratory mortalities, indicates that the long-term health aftermath of COVID-19 is still actively impacting public health.

3. Restructuring Health Infrastructure: With NCDs now accounting for over 60% of all mortalities, India’s public healthcare system requires a structural shift. Resources must pivot from traditional infectious disease management to preventive healthcare, primary diagnostic screening, and lifestyle disease management.

सैंपल रजिस्ट्रेशन System (SRS) रिपोर्ट 2024:

 1. कुल प्रजनन दर (Total Fertility Rate – TFR):

कुल प्रजनन दर का तात्पर्य एक महिला द्वारा अपने संपूर्ण प्रजनन काल में पैदा किए जाने वाले बच्चों की औसत संख्या से है।

• प्रतिस्थापन स्तर से नीचे (Below Replacement Level): भारत की टीएफआर लगातार पांचवें वर्ष प्रतिस्थापन स्तर (Replacement Level – 2.1) से नीचे 1.9 पर स्थिर बनी हुई है।

  • नोट: यदि टीएफआर 2.1 (स्थिर जनसंख्या स्तर) पर बनी रहे, तो जनसंख्या न तो बढ़ती है और न ही घटती है। भारत अब इससे नीचे आ चुका है।

• शहरी बनाम ग्रामीण विभाजन:

  • ग्रामीण भारत: टीएफआर 2.1 पर स्थिर है (सटीक प्रतिस्थापन स्तर पर)।

  • शहरी भारत: टीएफआर 1.5 के बेहद निचले स्तर पर है। शहरी क्षेत्रों में यह दर वर्ष 2005 के बाद से ही लगातार प्रतिस्थापन स्तर से नीचे बनी हुई है।

2. जन्म दर और लिंग अनुपात (Birth Rate & Sex Ratio):

• सकल जन्म दर (Crude Birth Rate – CBR): प्रति हजार जनसंख्या पर जन्म लेने वाले बच्चों की संख्या वर्ष 2023 के 18.4 से मामूली रूप से घटकर 2024 में 18.3 रह गई है।

  • ग्रामीण: 20.3 से घटकर 20.2 हुई।

  • शहरी: 14.9 से घटकर 14.7 हुई।

• जन्म के समय लिंग अनुपात (Sex Ratio at Birth): प्रति हजार बालकों पर जन्म लेने वाली बालिकाओं की संख्या (तीन वर्षीय औसत) में मामूली सुधार देखा गया है। यह 2021-23 के 917 से बढ़कर 2022-24 में 918 हो गया है।

 3. मृत्यु दर और चिंताजनक रुझान (Mortality Rates & Trends):

• सकल मृत्यु दर (Crude Death Rate – CDR): प्रति हजार जनसंख्या पर मौतों की संख्या 6.4 पर स्थिर है (ग्रामीण क्षेत्रों में 6.8 तथा शहरी क्षेत्रों में 5.6 से घटकर 5.5)।

• कोविड-19 से पूर्व की स्थिति से तुलना (चिंता का विषय): वर्तमान मृत्यु दर (6.4) अभी भी कोविड महामारी से ठीक पहले के वर्षों (2019 और 2020) के स्तर (6.0) से ऊपर बनी हुई है। हालांकि यह महामारी के सबसे घातक वर्ष 2021 (7.5) से बहुत कम है, लेकिन प्री-कोविड स्तर पर वापस न आना सार्वजनिक स्वास्थ्य के लिए चिंताजनक है।

• शिशु मृत्यु दर (Infant Mortality Rate – IMR): प्रति हजार जीवित जन्मों पर एक वर्ष से कम उम्र के बच्चों की मृत्यु दर में धीमी गति से सुधार जारी है। यह 2023 के 25 से घटकर 2024 में 24 पर आ गई है।

 4. मृत्यु के प्रमुख कारण (Causes of Death):

रिपोर्ट में मौतों के कारणों के बदलते स्वरूप (Epidemiological Transition) को भी रेखांकित किया गया है:

अ. श्वसन संबंधी संक्रमण (Respiratory Infections)

• श्वसन संक्रमण से होने वाली मौतों का अनुपात (तीन वर्षीय औसत) 2022-24 में 5.7% रहा। हालांकि यह महामारी के चरम दौर (2020-22 के 10%) से कम है, लेकिन कोविड-पूर्व स्तर (2017-19 के 3.6%) से अभी भी काफी अधिक है।

ब. गैर-संचारी रोग और हृदय रोग (NCDs & Cardiovascular Diseases)

• हृदय रोग (Cardiovascular Diseases): यह भारत में होने वाली मौतों का सबसे बड़ा कारण है। कुल मौतों में इसकी हिस्सेदारी 31% से बढ़कर 32.1% हो गई है। विशेषज्ञों के अनुसार, कोविड-19 के कारण हृदय रोगों से जुड़ी बीमारियाँ (Morbidity) दीर्घकालिक रूप से बढ़ी हैं।

• गैर-संचारी रोग (NCDs): श्वसन संक्रमण में कमी आने के साथ ही कैंसर, मधुमेह और हृदय रोग जैसे गैर-संचारी रोगों से होने वाली मौतों का कुल प्रतिशत 56.7% से बढ़कर 60.1% हो गया है।

स. दुर्घटनाएं और आत्महत्या (Accidents and Suicides)

• सड़क दुर्घटनाएं (Motor Vehicle Accidents): कुल मौतों में इनकी हिस्सेदारी 2.9% से बढ़कर 3.2% हो गई है।

• आत्महत्या (Suicide): आत्महत्या से होने वाली मौतों का हिस्सा 2.5% से बढ़कर 2.8% हो गया है।

  • सहायक डेटा: नेशनल क्राइम रिकॉर्ड्स ब्यूरो (NCRB) की ‘एक्सीडेंटल डेथ्स एंड सुसाइड्स इन इंडिया’ (ADSI) 2024 रिपोर्ट भी देश में सड़क दुर्घटनाओं और आत्महत्याओं के बढ़ते मामलों की पुष्टि करती है।

 मुख्य नीतिगत निष्कर्ष (Key Takeaways for Mains)

1. जनसंख्या स्थिरीकरण की ओर अग्रसर: लगातार 5 वर्षों तक TFR का 2.1 से नीचे रहना यह दर्शाता है कि भारत की जनसंख्या अब स्थिरीकरण (Stabilization) और भविष्य में क्रमिक गिरावट की ओर बढ़ रही है।

2. दीर्घकालिक ‘कोविड प्रभाव’: कोविड-19 महामारी के समाप्त होने के बाद भी हृदय रोगों और श्वसन संबंधी समस्याओं के कारण मृत्यु दर का प्री-कोविड स्तर से अधिक होना यह संकेत देता है कि महामारी के दीर्घकालिक स्वास्थ्य प्रभाव (Long COVID) अभी भी मौजूद हैं।

3. गैर-संचारी रोगों (NCDs) की चुनौती: भारत में 60% से अधिक मौतें अब गैर-संचारी रोगों के कारण हो रही हैं, जिसके लिए स्वास्थ्य बुनियादी ढांचे को प्राथमिक संक्रामक रोगों के नियंत्रण से हटाकर जीवनशैली जनित बीमारियों की रोकथाम की ओर मोड़ने की आवश्यकता है।

What exactly is SCAN?

• Location: It is located mainly in the primary motor cortex (M1), positioned between areas controlling specific body parts (like the hand, foot, or mouth).
• Whole-Body Control: Unlike traditional motor regions—which control specific, isolated movements—SCAN is “effector-agnostic,” meaning it works across the entire body rather than focusing on a single limb.

Main Function:

SCAN acts as a bridge between intention and action:

1. Cognitive Intention: You decide what you want to do.
2. Integration: SCAN integrates internal body signals, motivation, and physiology.
3. Planning: It helps plan and coordinate “whole-body” actions.
4. Execution: It sends refined commands to the motor systems for final execution.

In simple terms: SCAN is the “thinking → body coordination → action execution” system.

Key Features:

• Integration: It blends motor control (movement), cognitive goals (decision-making), and internal body states (heart rate, breathing, etc.).
• Complexity: It helps in complex, coordinated actions rather than just small, simple movements.
• Collaboration: It works closely with other networks, such as the cingulo-opercular network (the brain’s action control system).

Why is it important?

• Updated Brain Mapping: It challenges the old idea of a simple, linear “motor map” (the Homunculus) in the brain.
• Mind-Body Link: It proves that movement is deeply connected with our thoughts and physical physiology.
• Clinical Significance: It is increasingly linked to movement and neurological disorders, including:
  • Parkinson’s disease
  • Dystonia

 About the ANMOL Scheme:

• Comprehensive Testing: The scheme provides 56 different diagnostic tests for newborns to screen for genetic, metabolic, and congenital disorders.
• Single Sample Technology: All 56 tests are conducted using just one drop of blood (approximately 180 microlitres) taken from the newborn’s heel. It utilizes advanced Tandem Mass Spectrometry (TMS) technology.
• Zero Cost: These tests, which can cost between ₹15,000 and ₹25,000 in private labs, are now provided completely free in both government and private hospitals across Delhi.
• Targeted Disorders: It specifically screens for Inborn Errors of Metabolism (IEMs), congenital hypothyroidism, and other rare conditions that are often responsible for “unexplained infant mortality.”
• Budgetary Allocation: The government has earmarked ₹25 crore specifically for the rollout of this program in its first year.
• The “Golden Hour”: By screening babies ideally within 24 to 72 hours of birth, the scheme ensures that critical cases receive medical intervention during the “golden hour,” preventing long-term disabilities.

Significance for Public Health:

Democratizing Diagnostics:                    

Previously, such extensive 50+ test panels were accessible only to high-income families. ANMOL democratizes this access, ensuring that a child’s health outcome is not dictated by their family’s financial status.

Economic Impact:

Treating advanced genetic disorders can cost between ₹50,000 to over ₹10 lakh per year. Early screening allows for managed care or simple dietary interventions (like lactose-free milk or inexpensive thyroid medication) that can save families from crushing medical debt.

Integrated Emergency Response;

Alongside ANMOL, the budget also introduced a Real-Time Ventilator and Bed Vacancy Monitoring System. This ensures that if a newborn is diagnosed with a critical condition via ANMOL, parents can immediately locate a hospital with an available ICU bed or ventilator without wasting time.

Why in News? United Nations Inter-agency Group for Child Mortality Estimation (UNIGME) Report 2025 has identified India as a “key contributor” to the global and regional reduction of under-five and neonatal mortality. The report specifically praises India’s ability to scale up public health interventions in a populous and diverse environment, leading to one of the fastest reductions in child deaths globally.

Key Points from the Report:

1. Statistical Progress (Regional & National):

• South Asia’s Decline: The region saw a 76% decline in under-five deaths since 1990 and a 68% drop since 2000.
• Mortality Rates: Under-five mortality in the region fell from 92 deaths per 1,000 live births in 2000 to approximately 32 in 2024.
• Neonatal & Early Childhood: Neonatal deaths (first 28 days) declined by nearly 60%, while mortality for children aged 1–59 months dropped by over 75% since 2000.

2. Strategic Interventions:

The report attributes this success to a “continuum-of-care” strategy and several flagship Indian schemes:

• Institutional Delivery: Programs like Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakram (JSSK) have incentivized hospital births and free care for newborns.
• Immunization: The Universal Immunisation Programme (UIP) has been scaled up to ensure broader coverage against preventable diseases.
• Infrastructure: Expansion of Special Newborn Care Units (SNCU) and the use of digital health innovations like Tele-SNCU.
• Clinical Management: Implementation of the Integrated Management of Neonatal and Childhood Illnesses (IMNCI).

3. Challenges & Leadership:

• Global Share: Despite the progress, South Asia still accounts for nearly 25% of global under-five deaths, highlighting the need for continued momentum.
• India’s Role: India is positioned as a leader among high-burden countries, proving that equity-driven and standards-led interventions can yield rapid results even in complex settings.

• The Target: Approximately 1.15 crore (11.5 million) girls aged 14 will be vaccinated annually.

• The Vaccine: The government is using Gardasil (a quadrivalent vaccine) provided free of cost at government health centers (Ayushman Arogya Mandirs).

• The Strategy: Unlike routine immunization, this is a “special drive” tracked via the U-WIN portal (similar to CoWIN).

• Dose Regimen: India has adopted a single-dose schedule based on recent WHO and NTAGI (National Technical Advisory Group on Immunisation) recommendations, which found one dose provides robust, long-term protection for this age group.

What is HPV?

HPV stands for Human Papillomavirus. It is actually a group of more than 200 related viruses. It is the most common sexually transmitted infection (STI) globally—so common that nearly all sexually active people will get it at some point in their lives if they aren’t vaccinated.

• Low-Risk HPV: These types (like HPV 6 and 11) usually cause genital warts. They are uncomfortable but do not cause cancer.

• High-Risk HPV: These types (like HPV 16 and 18) can cause cancers. They often have no symptoms until the cancer has actually started to develop.

• What can it cause?

While the body’s immune system clears the virus on its own in 90% of cases within two years, persistent infections can lead to:

• Cervical Cancer: Almost all cases are caused by HPV.

• Other Cancers: It can also cause cancer of the anus, throat (oropharyngeal), penis, vagina, and vulva.

• Warts: Common warts on hands/feet or genital warts.

3. How is it spread?

HPV is spread through intimate skin-to-skin contact.

• It is most commonly passed during vaginal, anal, or oral sex.

• Important Note: Because it is skin-to-skin, condoms do not provide 100% protection (though they significantly reduce the risk), as the virus can be on skin not covered by the condom.

4. Prevention & Treatment:

• Vaccination: This is the most effective tool. Vaccines like Gardasil are highly effective if given before a person becomes sexually active (ideally between ages 9–14).

• Screening: For women, regular Pap smears or HPV tests can find “precancerous” cells before they ever turn into cancer.

• Treatment: There is no cure for the virus itself, but doctors can treat the health problems it causes, such as removing warts or treating precancerous cell changes.

What is Cyberchondria?

Cyberchondria is a clinical phenomenon where an individual’s anxiety regarding their health is worsened by excessive or repeated online searches for medical information. Unlike traditional hypochondria, it is specifically driven by the algorithm-led nature of the internet.

The Mechanics: How it Works?

• The Escalation Trap: A user searches for a minor symptom (e.g., a headache). Search engines and AI tools, optimized for “engagement” or “worst-case accuracy,” often rank rare but serious conditions (e.g., brain tumor) higher, leading the user to believe they are seriously ill.
• Algorithmic Bias: Modern AI-powered health tools may lack the “clinical nuance” of a doctor, failing to distinguish between common symptoms and life-threatening emergencies.
• Echo Chambers: Social media algorithms suggest “patient support groups” or health forums based on search history, further validating the user’s fears.

Impacts on Vulnerable Groups (Adolescents):

The recent feature in The Hindu highlights that adolescents are at the highest risk due to:

• Digital Fantasies: The tendency to trust AI/Digital avatars more than traditional practitioners.
• Brain Plasticity: Teenagers are more prone to “health-related obsessive-compulsive behaviors” triggered by digital triggers.
• Social Isolation: Cyberchondria leads to a “feedback loop” where the youth withdraw from physical activities, further deteriorating mental well-being.

Societal and Healthcare Challenges :

• Doctor-Patient Conflict: Increased “Self-Diagnosis” leads to mistrust in doctors, as patients arrive at clinics with pre-conceived (and often incorrect) AI-generated reports.
• Burden on Healthcare: Unnecessary diagnostic tests requested by “anxious searchers” drain public and private medical resources.
• Digital Divide: While urban users suffer from “information overload,” rural users may lack access to even basic digital literacy to verify these AI claims.

Mitigating Strategies:

• Digital Hygiene: Encouraging users to stick to verified government portals (like MoHFW or WHO) rather than open-ended AI chatbots.
• The “Human-in-the-Loop” Approach: AI health tools must have a mandatory disclaimer and a direct “Tele-consultation” link to a real doctor to break the anxiety cycle.

Media Literacy: Integrating “Digital Health Literacy” into the school curriculum to teach students how to interpret medical data online

Key Legislative Changes:

The passing of this Bill triggers major amendments across three primary legislative frameworks:

• The Insurance Act, 1938

• The Life Insurance Corporation Act, 1956

• The Insurance Regulatory and Development Authority Act, 1999

Objectives and Economic Impact:

Union Finance Minister Nirmala Sitharaman highlighted several benefits intended to strengthen the national economy and insurance landscape:

• Increased Penetration: The move aims to bring insurance coverage to a larger portion of the population.

• Lower Premiums: Enhanced competition and capital flow are expected to reduce premium costs for citizens.

• Job Creation: The expansion of the sector is projected to create new employment opportunities.

• Operational Independence: Foreign companies can now operate in India even if they are unable to secure a local joint venture partner.

• Entry of Smaller Players: The requirement for net owned funds has been slashed from Rs 5,000 crore to Rs 1,000 crore, allowing smaller companies to enter the market.

Historical Context of FDI in Insurance:

The increase to 100% marks the final stage in a decade-long liberalization of the sector:

• 2015: FDI limit increased from 26% to 49%.

• 2021: FDI limit increased from 49% to 74%.

• 2025: FDI limit increased to 100%.

Opposition Concerns:

Despite its passage, the Bill faced significant pushback from opposition members:

• Parliamentary Review: The House rejected a demand to send the Bill to a parliamentary panel for further scrutiny.

• Linguistic Objections: Opposition members objected to the use of both Hindi and English words in the Bill’s official title.

• Rural Market Protections: TMC’s Saket Gokhale argued that private insurers may ignore low-premium, high-risk rural markets, potentially hampering government-provided protections.

• Predatory Pricing: Concerns were raised regarding private companies entering the market with predatory pricing, which could affect the market share and profits of LIC.

• Policy Inconsistency: Congress MP Shaktisinh Gohil noted that past BJP leaders and the party’s 2014 manifesto had previously opposed allowing FDI in the insurance sector.

 About the Insurance Act, 1938:

The “Parent” Law This is the original, comprehensive legislation created during British rule to regulate the insurance business in India.

• Purpose: It was designed to bring all types of insurance (Life and General) under a single regulatory system to prevent fraud and protect policyholders from “fly-by-night” operators.

• Key Features: * Mandated the compulsory registration of all insurance companies.

  • Set rules for how companies could invest their funds (ensuring they kept enough money to pay claims).

  • Established the position of the Controller of Insurance, the very first insurance regulator in India.

About the Life Insurance Corporation (LIC) Act, 1956:

The “Nationalization” Law In the 1950s, the Indian government decided that life insurance was too important for the private sector alone and should be used to fund national development.

• Purpose: This Act nationalized the life insurance industry by merging 245 Indian and foreign insurers into one single entity: the Life Insurance Corporation of India (LIC).

• Key Features:

• Gave LIC the exclusive right (monopoly) to carry out life insurance business in India.
• Provided a Sovereign Guarantee, meaning the Government of India would be responsible for paying policyholders if LIC ever failed.
• Mandated that LIC invest heavily in government-approved projects like housing, water supply, and infrastructure.

About the IRDA Act, 1999:

The “Liberalization” Law By the late 90s, the government realized that a monopoly was slowing down growth and innovation. This Act reopened the door to the private sector.

• Purpose: It established the Insurance Regulatory and Development Authority (IRDA) as an independent, statutory body to oversee and develop the industry.

• Key Features:

• Ended the monopoly of LIC (Life) and GIC (General), allowing private companies to enter the market again.
• Introduced Foreign Direct Investment (FDI) to bring in global capital and expertise.
• Gave the IRDA the power to issue licenses, set code-of-conduct rules for agents, and protect policyholder interests through a Grievance Redressal system.

• Core Achievement: The deal is expected to deliver substantial financial savings, which will be used to procure millions of additional vaccine doses, leading to expanded protection for children against malaria.

About the R21/Matrix-M Vaccine Deal:

New Price: The price of the vaccine is expected to fall to $2.99 per dose, with this change anticipated to take effect in approximately one year.

Savings Generated: The agreement is expected to generate up to $90 million in savings for Gavi and the

Children Protected: The deal is projected to enable the full vaccination of nearly seven million more children against malaria over the next five years.

Executing Agency: The agreement was formally executed by UNICEF, which holds the position of the world’s largest buyer of vaccines.

Gavi’s Role: Gavi facilitates and finances the procurement, logistics, and integration of malaria vaccines into national immunisation programmes.

Current Reach: The Gavi programme has already delivered over 40 million doses of malaria vaccines, which are currently part of routine immunisation in 24 African countries (these countries represent over 70% of the world’s malaria burden).

Malaria Vaccines in Use: The World Health Organization (WHO) has prequalified two malaria vaccines: R21/Matrix-M and RTS,S/AS01.

R21 Development: The R21/Matrix-M vaccine was co-developed by the University of Oxford and the Serum Institute of India (SII), utilizing Novavax’s Matrix-M adjuvant technology.

 Innovative Mechanism: IFFIm

The agreement’s financing was enabled by an innovative financial tool: the International Finance Facility for Immunisation (IFFIm) mechanism.

• Financing: The deal is financed by Gavi through an advance payment made possible by IFFIm.
• IFFIm Function: IFFIm is a mechanism that converts long-term donor pledges into immediately available cash by issuing Vaccine Bonds on the capital markets.
• Purpose: This mechanism provides Gavi with the agility to act quickly when market-shaping opportunities arise, such as securing this reduced, equitable pricing for the malaria vaccine.

About GAVI:

GAVI, officially known as Gavi, the Vaccine Alliance, is a global health partnership dedicated to increasing access to immunization in the world’s poorest countries.

Mission and Purpose:

Gavi was founded in 2000 as a public-private partnership with the core goal of saving children’s lives and protecting people’s health by increasing the equitable and sustainable use of vaccines. It focuses particularly on reaching “zero-dose children”—those who have not received even a single routine vaccine shot.

Impact and Results:

Since its inception, Gavi has achieved significant results in global health:

• Lives Saved: It has helped vaccinate over 2 billion children in 78 lower-income countries, which has prevented more than 20.6 million future deaths.
• Child Mortality: Its efforts have contributed to halving child mortality in the countries it supports.
• Economic Benefits: For every US$1 spent on immunization in Gavi-supported countries, an estimated **US$54** in broader economic benefits is generated, including health care savings and increased productivity.
• Disease Prevention: It supports the introduction and delivery of vaccines against deadly diseases such as cholera, Ebola, yellow fever, meningitis, and the Pentavalent vaccine (which protects against Diphtheria, Tetanus, Pertussis, Haemophilus influenzae type b, and Hepatitis B).